The Methodist Hospital Research Institute
Clinical trials sponsored by The Methodist Hospital Research Institute, explained in plain language.
-
Could two drugs together tame tough breast cancer?
Disease control OngoingThis early-stage trial tests the safety of combining two drugs, olaparib and vorinostat, for people with breast cancer that has returned or spread. The study includes 28 adults with certain types of advanced breast cancer. The goal is to find the best dose and see if the combinat…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 05:48 UTC
-
New Triple-Drug attack shows promise against aggressive breast cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (durvalumab) to two standard HER2-targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in women with a specific, aggressive type of breast cancer called HER2-enriched. About 51 women with early-stage,…
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
New drug before surgery may stop melanoma from coming back
Disease control OngoingThis study tests if giving the drug atezolizumab before surgery is safe for people with high-risk melanoma that hasn't spread. About 20 adults will receive two doses before their tumor is removed. The goal is to see if this approach can lower the chance of the cancer returning wi…
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
Bladder cancer vaccine trial shows promise without chemo
Disease control OngoingThis study tests a new approach for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The treatment combines an immunotherapy drug (sasanlimab) with targeted radiation to help the body's immune system fight the tumor before surgery. The goal is …
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug may stop kidney transplants from failing
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding the drug belumosudil to standard anti-rejection medicines can prevent scarring in new kidney transplants. Scarring often leads to transplant failure over time. About 40 adults receiving a first or second kidney will take either the drug or a placeb…
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Lower pressure tourniquets may cut Post-Op pain and opioid use
Symptom relief OngoingThis study tests whether using a lower, personalized tourniquet pressure during orthopedic surgery can reduce pain and the need for painkillers afterward. Standard tourniquets use high pressure, which can cause muscle weakness and pain. The new method, called Limb Occlusion Press…
Phase: NA • Sponsor: The Methodist Hospital Research Institute • Aim: Symptom relief
Last updated May 15, 2026 11:57 UTC
-
Wrist fracture rehab gets a boost: blood flow restriction may speed recovery
Symptom relief OngoingThis study tests whether adding blood flow restriction (BFR) therapy to standard physical therapy helps people regain strength and muscle mass after wrist fracture surgery. About 70 adults who had surgery for a broken wrist will either get standard rehab or standard rehab plus BF…
Phase: NA • Sponsor: The Methodist Hospital Research Institute • Aim: Symptom relief
Last updated May 15, 2026 11:55 UTC
-
New antibiotic delivery method tested in shoulder surgery
Knowledge-focused OngoingThis study looks at two methods of giving the antibiotic vancomycin during shoulder replacement surgery: standard IV (into a vein) versus intraosseous (into the bone). Researchers want to see if both methods deliver similar levels of the drug to bone and tissue. About 33 adults h…
Phase: PHASE4 • Sponsor: The Methodist Hospital Research Institute • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC